Nabi Biopharmaceuticals (NABI) Reports Q3 Loss of $0.07, Sales Fall Short
Tweet
Share
E-mailGet Alerts NABI Hot Sheet
Price: $1.80 --0%
Financial Fact:
General and administrative expenses: 2.2M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
General and administrative expenses: 2.2M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Nabi Biopharmaceuticals (NASDAQ: NABI) reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $5 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Stratasys (SSYS) Tops Q2 EPS by 2c ;; Offers Guidance
- Pulmatrix (PULM) Reports Q2 Loss of $0.29
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
